Integritas Communications is pleased to announce a series of complimentary Continuing Medical Education (CME) meetings focused on evolving models of HIV care. This accredited meeting series titled, “HIV Experts & Evidence™ Evolving Models of HIV Care: Volume 2: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice,” is designed for infectious diseases and HIV-specialist physicians, as well as primary care providers (PCPs) and other community stakeholders involved in the care of patients with HIV infection. Healthcare professionals are able to request a CME/CNE/CPE-accredited dinner meeting at a convenient date and time to meet their individual needs.
Best-practice recommendations for treatment of patients infected with human immunodeficiency virus (HIV) are continually evolving and now include strategies related to early initiation of antiretroviral therapy (ART) in patients with newly diagnosed HIV. This HIV Experts and Evidence™ live meeting series will present recent data related to rapid ART initiation, solutions to logistical and clinical barriers that can impede access to same-day ART regimens, and real-world approaches to enhanced retention in care.
Top faculty members in the field of HIV/AIDS will lead the “HIV Experts & Evidence™ Evolving Models of HIV Care: Volume 2: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice” meetings. The Course Co-Chairs are Dr. Jonathan Colasanti and Dr. Jason Halperin, and Dr. Paul Sax is the Course Faculty Advisor. Dr. Richard Elion, Dr. Joseph Eron, Jr, Dr. Serena Koenig, Dr. Mary Montgomery, Dr. Allan Rodriguez, and Dr. Sarah Rowan round out the list of expert speakers for the HIV accredited meetings.
Upon successful completion of the HIV CME activity, participants should be better able to:
- Reduce time from HIV diagnosis to viral suppression to improve patient outcomes and prevent HIV transmission;
- Select appropriate regimens for rapid ART initiation based on current guidelines and patient characteristics; and
- Implement strategies designed to decrease barriers to the provision of rapid ART to patients with newly diagnosed HIV infection.